Status:
UNKNOWN
Comparison of Epithelial Lining Fluid and Blood Pharmacokinetics and Pharmacodynamics of Intravenous and Intravenous Plus Nebulized Polymyxin B in Multidrug Resistant Bacteria Ventilator-associated Pneumonia Patients
Lead Sponsor:
Southeast University, China
Conditions:
Polymyxin B
Ventilator-associated Pneumonia
Eligibility:
All Genders
18-85 years
Brief Summary
The goal of this observational study is to investigate whether intravenous polymyxin B combined with nebulisation achieves better antimicrobial efficacy and clinical outcomes than intravenous use alon...
Eligibility Criteria
Inclusion
- 18-80 years old;
- ICU patients;
- Patients with MDR-infected VAP were diagnosed by etiological culture results;
- Expect to receive at least 6 doses (3 days) of polymyxin B;
- Obtain informed consent;
Exclusion
- The patient has a history of severe hypersensitivity to polymyxin B;
- Patients cannot tolerate alveolar lavage;
- Oncology patients,includes hematologic malignancies;
- Pregnant or lactating women;
- Patients with other conditions that the investigators consider unsuitable for enrollment;
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06076603
Start Date
July 1 2023
End Date
August 1 2024
Last Update
October 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital Affiliated to Southeast University
Nanjing, Jiangsu, China, 210009